Granted preliminary injunction restraining Professional Compounding Centers of America, Inc. "from acting directly or indirectly" to sell pentamidine or contract doctors, hospitals, or pharmacists to solicit orders for the drug. In a May 23 motion filed in Houston federal court, Lyphomed accused Professional Compounding Centers of "selling bulk pentamidine, without FDA approval, to pharmacies." A trial date will be scheduled "shortly after Sept. 1, 1989," the injunction states.
You may also be interested in...
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.